ITIH5 and urinary bladder cancer: ECRG4 and ITIH5 methylation were both significantly increased in the urine samples from patients with cancers of the bladder (ECRG4 mean PMR: 5.011, 95% CI: 2.118–7.905; ITIH5 mean PMR: 2.634, 95% CI: 0.730–4.539), the prostate (ECRG4 mean PMR: 1.306, 95% CI: 0.178–2.434; ITIH5 mean PMR: 1.018, 95% CI: 0.441–1.720), and the kidney (ECRG4 mean PMR: 0.985, 95% CI: 0.188–1.781, ITIH5 mean PMR: 1.311, 95% CI: 0.147–2.475) when compared to healthy controls (ECRG4 mean PMR: 0.017, 95% CI: <0.001–0.033, ITIH5 mean PMR: 0.031, 95% CI: 0.009–0.070).